Reproductive factors and the endometrial cancer morbidity

Introduction: Endometrial cancer is one of the most common cancers among women of highly developed countries. Purpose: The purpose of the study was to evaluate the selected reproductive factors increasing or decreasing the odds ratio (OR) of endometrial cancer in women. Material and Methods: The study involved 400 women aged 40 to 84 years of Obstetrics and Gynecology University Hospital in Poznań. It evaluated parameters such as age, anthropometric data (body weight, height). In addition, number of births and miscarriages, age of the first and last menstruation, the age at which the first child was born, duration of breastfeeding, use of hormonal contraception, and co-morbidities were analyzed. Results: Women menstruating over the age of 55 years are characterized with nearly eight-fold increased risk of endometrial cancer (OR = 8.8, 95% Cl 1.348–57.428). The OR of developing the cancer in women giving the first birth between 20 and 25 years of age is OR= 0.297; 95% Cl 0.307–0.969, and in women between 26 and 30 years of age OR = 0.218; 95% Cl 0.073–0.650 when compared to women giving birth to their first child below 20 years of age. Conclusions: Women menstruating over 55 years of age and using hormonal contraception have an increased risk of developing endometrial cancer.

Reproductive factors; Menopause; Contraception.

[1] Santoso J.T., Barton G., Riedley-Malone S., Wan J.Y.: “Obesity and perioperative outcomes in endometrial cancer surgery”. Arch. Gynecol. Obstet., 2012, 4, 1139.

[2] Plagens – Rotman K., Żak E., Pięta B.: “Odds ratio analysis in women with endometrial cancer”. Prz. Menopauz., 2016, 1, 12.

[3] Zhu C., Luo J., Shi H., Xie X., Ding Z..: “Expression of tubulin, p53, Ki67, receptors for estrogen, and progesterone in endometrial cancer”. Eur. J. Gynecol. Oncol., 2009, 30, 514.

[4] Bittoni M.A., Fisher J.L., Fowler J.M., Maxwell G.L., Paskett E.D.: “Assessment of the effects of severe obesity and lifestyle risk factors on stage of endometrial cancer”. Cancer Epidemiol. Biomarkers Prev., 2013, 1, 76.

[5] Farthing A., Chatterjee J., Joglekar – Pai P., Dorney E., GhaemMaghami S.: “Total laparoscopic hysterectomy for early stage endometrial cancer in obese and morbidly obese women”. J. Obstet. Gynaecol., 2012, 6, 580.

[6] Thomas M., Mariani A., Wright J.D., Maderek E.O., Powell M. A., Mutch D. G., et. al.: “Surgical management and adjuveant therapy for patients with uterine clear cel carcinoma: a multi – institutional review”. Gynecol. Oncol., 2008, 108, 293.

[7] Colombo N., Preti E., Landoni F., Carinelli S., Colombo A., Marini C., et al.: “ESMO Guidelines Working Group: Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow – up”. Ann. Oncol., 2013, 24, vi33.

[8] Amankwah E.K., Friedenreich C.M., Magliocco A.M., Brant R., Speidel T., Rahman W., Cook L.S.: “Hormonal and reproductive risk factors for sporadic microsatellite stable and unstable endometrial tumors”. Cancer Epidemiol. Biomarkers Prev., 2013, 7, 1325.

[9] Setiawan V.W., Pike M.C., Karageorgi S., Deming S.L., Anderson K., Bernstein L., et al.: “Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium”. Am. J. Epidemiol., 2012, 4, 269.

[10] Zhan B., Liu X., Li F., Zhang D.: “Breastfeeding and the incidence of endometrial cancer: A meta – analysis”. Oncotarget., 2015, 35, 38398.

[11] Sugawara Y., Kakizaki, M. Nagai, M., Tomata, Y., Hoshi R., Watanabr I., et al.: “Lactation pattern and the risk for hormone – related female cancer in Japan: The Ohsaki Cohort Study”. Eur. J. Cancer Prev., 2013, 22, 187.

[12] Xu W.H., Xiang Y.B., Ruan Z.X., Zheng W., Cheng J. R., Dai Q., et al.: “Menstrual and reproductive factors and endometrial cancer risk: Results from a population – based case – control study in urban Shanghai”. Int. J. Canc., 2004, 108, 613.

[13] Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitti D.: “Hormone replacement therapy and endometrial cancer risk: a metaanalysis”. Obstet. Gynecol., 1995, 85, 304.

[14] Ghanbari Andarieh M., Agajani Delavar M., Moslemi D., Esmaeilzadeh S.: “Risk Factors for Endometrial Cancer: Results from a Hospital – Based Case – Control Study”. Asian Pac. J. Cancer Prev., 2016, 10, 4791.

[15] Beral V., Bull D., Reeves G., Million Women Study Collaborators.: Endometrial cancer and hormone-replacement therapy in the Million Women Study”. Lancet. 2005, 6, 1543.

[16] Iversen L., Sivasubramaniam S., Lee A.J., Fielding S., Hannaford PC.: “Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study”. Am J Obstet Gynecol., 2017, 216, 580.e1.

[17] Baloglu A., Bezircioglu I., Cetinkaya B., Hicyılmaz L.: “Prospective clinical study of the association between plasma level of free IGF-1 and myometrial invasion in patients with endometrial adenocarcinoma”. Ginekol Pol., 2010, 81, 501.

[18] Kancalska – Janssen O., Rajtar – Ciosek., Zmaczyński A., Wyroba J., Milewicz T., Krzyczkowska-Sendrakowska M., Krzysiek J..: “Markers of insulin resistance in perimenopausal women with endometrial pathology”. Ginekol Pol. 2013, 84, 922.

[19] Li C., Balluz L.S., Ford E.S., Okoro C.A., Tsai J., Zhao G.: “Association between diagnosed diabetes and self – reported cancer among U.S. adults: findings from the 2009 Behavioral Risk Factor Surveillance System”. Diabetes Care, 2011, 34, 1365.

[20] Sun W., Lu J., Wu S., Bi Y., Mu Y., Zhao J., et al.: “Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non – diabetic women”. Am. J. Cancer Res., 2016, 1, 2334.

[21] Wise M.R., Gill P., Lensen S., Thompson J.M., Farquhar C.M.: “Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women”. Am. J. Obstet. Gynecol., 2016, 5, 598.e1.

[22] Sponholtz T.R., Palmer J.R., Rosenberg L., Hatch E.E., Adams-Campbell L.L, Wise L.A.: “Body Size, Metabolic Factors, and Risk of Endometrial Cancer in Black Women”. Am. J. Epidemiol., 2016, 4, 259.